IP Library › Granted Patent US 7,183,396
Granted Patent B2
US 7,183,396 · App. 10/244,586 · Granted Feb 27, 2007

Linvin, a novel inhibitor of apoptosis protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,183,396
App. No.
10/244,586
Granted
Feb 27, 2007
Kind
B2
Abstract

A novel isolated and purified human protein inhibitor of apoptosis, termed livin, is described. A cDNA sequence which encodes the native inhibitor of apoptosis (livin) is disclosed as well as the structural coding region and the amino acid residue sequence. Molecular sequences are provided for the design and synthesis of entities that modulate biological and/or pharmacological activity of the native biomolecule. Methods are provided which employ the sequences to identify compounds that modulate biological and/or pharmacological activity of the native biomolecule. Biologically-effective antisense molecules as well as dominant negative mutant versions of the livin protein which are suitable for therapeutic are also provided. The invention is also drawn toward the study, prevention, diagnosis, and treatment of pathophysiological disorders related to apoptosis.

Claims (7)

1. An isolated and/or purified polynucleotide molecule comprising a nucleic acid sequence which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

2. An expression vector comprising the polynucleotide of claim 1 .

3. A cultured host cell transformed or transfected with the expression vector of claim 2 .

4. An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2, or a nucleotide sequence fully complementary thereto.

5. A method of producing a polypeptide comprising culturing a host cell transformed or transfected with an expression vector comprising a polynucleotide which encodes the polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

6. The method of claim 5 , additionally comprising purifying the polypeptide from the cells or the culture medium.

7. An oligomer which is the complete complement to the sequence selected from the group consisting of positions 194–206; 195–207; 196–208; 197–209; 198–210; 199–211, 200–212; 201–213; 202–214; 203–215; 204–216; 205–217; 206–218; 207–219; 208–220; 209–221; 210–222; 211–223; 212–224; 213–225; 214–226; 215–227; 216–228; 220–232; 225–237; 230–242; 240–252; 250–262; 270–282; 520–532; 525–537; 529–541; 530–542; 555–567; 560–572; 570–582; 590–602; and 600–612 of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2007
From: GOMES, BRUCE C.; KASOF, GARRETT M.; PROSSER, JUDITH C.
To: ZENECA LIMITED
Reel/Frame 018803/0306 →
CHANGE OF NAME Recorded Jan 23, 2007
From: ZENECA LIMITED
To: SYNGENTA LIMITED
Reel/Frame 018804/0437 →
Continuity (1)
Related Publication 20030087319A1 · May 8, 2003